Posted On: 08/22/2016 7:16:04 PM
Post# of 72447
Re: Loose Lips #26641
Based on recent deals, an effective cancer drug against one solid tumor type is worth about $5B-10B. We all know how much Imbruvica was sold for. Kevetrin has the potential to treat both solid and blood cancers. That's why I was disappointed when the AML trial was put on hold due to lack of funding.
I agree that if the K-OC trial is successful, CTIX should have no problem finding partners for other indications.
I agree that if the K-OC trial is successful, CTIX should have no problem finding partners for other indications.
Quote:
Likely it will get to market for ovarian cancer first, but when CTIX secures a partnership and funding from the other drugs, they may be able to open up several other pathways for K in parallel with the ovarian cancer indication.
(0)
(0)
